Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec;9(4):896-906.
doi: 10.1177/23969873241249295. Epub 2024 May 10.

Outcomes of mechanical thrombectomy in anticoagulated patients with acute distal and medium vessel stroke

Hamza Salim  1   2 Basel Musmar  3 Nimer Adeeb  4 Vivek Yedavalli  1 Dhairya Lakhani  1 Sahibjot Singh Grewal  5 Kareem El Naamani  3 Nils Henninger  6 Sri Hari Sundararajan  7 Anna Luisa Kühn  8 Jane Khalife  9 Sherief Ghozy  10 Luca Scarcia  11 Benjamin Yq Tan  12   13 Robert W Regenhardt  2 Jeremy J Heit  14 Nicole M Cancelliere  5 Joshua D Bernstock  15 Aymeric Rouchaud  16 Jens Fiehler  17 Sunil Sheth  18 Ajit S Puri  8 Christian Dyzmann  19 Marco Colasurdo  20 Xavier Barreau  21 Leonardo Renieri  22 João Pedro Filipe  23 Pablo Harker  24 Răzvan Alexandru Radu  25 Mohamad Abdalkader  26 Piers Klein  26 Thomas R Marotta  5 Julian Spears  5 Takahiro Ota  27 Ashkan Mowla  28 Pascal Jabbour  3 Arundhati Biswas  29 Frédéric Clarençon  30 James E Siegler  9 Thanh N Nguyen  26 Ricardo Varela  31 Amanda Baker  32 Muhammed Amir Essibayi  32 David Altschul  32 Nestor R Gonzalez  33 Markus A Möhlenbruch  34 Vincent Costalat  25 Benjamin Gory  35   36 Christian Paul Stracke  37 Mohammad Ali Aziz-Sultan  15 Constantin Hecker  38 Hamza Shaikh  9 David S Liebeskind  39 Alessandro Pedicelli  40 Andrea M Alexandre  40 Illario Tancredi  41 Tobias D Faizy  42 Erwah Kalsoum  11 Boris Lubicz  43 Aman B Patel  2 Vitor Mendes Pereira  5 Adrien Guenego  43 Adam A Dmytriw  2   5 MAD MT Investigators
Collaborators, Affiliations
Multicenter Study

Outcomes of mechanical thrombectomy in anticoagulated patients with acute distal and medium vessel stroke

Hamza Salim et al. Eur Stroke J. 2024 Dec.

Abstract

Background: Stroke remains a major health concern globally, with oral anticoagulants widely prescribed for stroke prevention. The efficacy and safety of mechanical thrombectomy (MT) in anticoagulated patients with distal medium vessel occlusions (DMVO) are not well understood.

Methods: This retrospective analysis involved 1282 acute ischemic stroke (AIS) patients who underwent MT in 37 centers across North America, Asia, and Europe from September 2017 to July 2023. Data on demographics, clinical presentation, treatment specifics, and outcomes were collected. The primary outcomes were functional outcomes at 90 days post-MT, measured by modified Rankin Scale (mRS) scores. Secondary outcomes included reperfusion rates, mortality, and hemorrhagic complications.

Results: Of the patients, 223 (34%) were on anticoagulation therapy. Anticoagulated patients were older (median age 78 vs 74 years; p < 0.001) and had a higher prevalence of atrial fibrillation (77% vs 26%; p < 0.001). Their baseline National Institutes of Health Stroke Scale (NIHSS) scores were also higher (median 12 vs 9; p = 0.002). Before propensity score matching (PSM), anticoagulated patients had similar rates of favorable 90-day outcomes (mRS 0-1: 30% vs 37%, p = 0.1; mRS 0-2: 47% vs 50%, p = 0.41) but higher mortality (26% vs 17%, p = 0.008). After PSM, there were no significant differences in outcomes between the two groups.

Conclusion: Anticoagulated patients undergoing MT for AIS due to DMVO did not show significant differences in 90-day mRS outcomes, reperfusion, or hemorrhage compared to non-anticoagulated patients after adjustment for covariates.

Keywords: Stroke; anticoagulation; thrombectomy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Regenhardt serves on a DSMB for a trial sponsored by Rapid Medical, serves as site PI for studies sponsored by Penumbra and Microvention, and receives stroke research grant funding from the National Institutes of Health, Society of Vascular and Interventional Neurology, and Heitman Stroke Foundation.Dr. Guenego reports consultancy for Rapid Medical and Phenox, not directly related to the present work.Dr. Clarençon reports conflicts of interest with Medtronic, Balt Extrusion (consultant), ClinSearch (core lab), Penumbra, Stryker (payment for reading) and Artedrone (Board); all not directly related to the present work.Dr. Henninger received support from W81XWH-19-PRARP-RPA form the CDMRP/DoD, NS131756 and U24NS113844 from the NINDS, and NR020231 from the NINR and received compensation from Myrobalan, Inc. and General Dynamics during the conduct of this study unrelated to this work.Dr. Liebeskind is consultant as Imaging Core Lab to Cerenovus, Genentech, Medtronic, Stryker, Rapid Medical.Dr. Yeo reports Advisory work for AstraZeneca, Substantial support from NMRC Singapore and is a medical advisor for See-mode, Cortiro and Sunbird Bio, with equity in Ceroflo. All unrelated to the present work.Dr. Griessenauer reports a proctoring agreement with Medtronic and research funding by Penumbra.Dr. Marnat reports conflicts of interest with Microvention Europe, Stryker Neurovascular, Balt (consulting), Medtronic, Johnson & Johnson and Phenox (paid lectures), all not directly related to the present work.Dr. Puri is a consultant for Medtronic Neurovascular, Stryker NeurovascularBalt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical, he received research grants from NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular, and holds stocks in InNeuroCo, Agile, Perfuze, Galaxy and NTI.Dr. Tjoumakaris is a consultant for Medtronic and Microvention (funds paid to institution, not personally).Dr. Jabbour is a consultant for Medtronic, Microvention and Cerus.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Bar charts display the percentage distribution of 90-day modified Rankin Scale (mRS) scores for stroke patients.

References

    1. Townsend N, Nichols M, Scarborough P, et al.. Cardiovascular disease in Europe–epidemiological update 2015. Eur Heart J 2015; 36: 2696–2705. - PubMed
    1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al.. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245–255. - PMC - PubMed
    1. Park TH, Ko Y, Lee SJ, et al.. Identifying target risk factors using population attributable risks of ischemic stroke by age and sex. Stroke 2015; 17: 302–311. - PMC - PubMed
    1. Sanna T, Diener HC, Passman RS, et al..; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. New Engl J Med 2014; 370: 2478–2486. - PubMed
    1. Barrios V, Escobar C, Calderón A, et al.. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Española Cardiol Engl Ed 2014; 67: 150–151. - PubMed

Publication types